1)北京生命科技研究院有限公司,北京 102200;2)国家烟草质量监督检验中心,烟草生物学效应重点实验室,郑州 450001;3.4)中国科学技术大学,合肥 230026;4.5)中国科学院合肥物质科学研究院,合肥 230031;5.3)湖北中烟工业有限责任公司新型烟草制品工程中心,武汉 430040;6.1)北京生命科技研究院,北京 102200
北京生命科技研究院青年人才项目(2024100CC0110),国家烟草质量监督检验中心青年人才托举工程项目(552024CR0010),中国烟草总公司基础研究项目(110202403001),湖北中烟工业有限责任公司科技项目(2023JCXX3GC2A002)资助和湖南中烟工业有限责任公司科技项目(KY2026JC0023)。
1)Beijing Life Science Academy, Beijing 102200, China;2)China National Tobacco Quality Supervision & Test Center, Key Laboratory of Tobacco Biological Effects, Zhengzhou 450001, China;3.4)University of Science and Technology of China, Hefei 230026, China;4.5)Hefei Institute of Physical Sciences, Chinese Academy of Sciences, Hefei 230031, China;5.3)New Tobacco Products Engineering Center, China Tobacco Hubei Industrial Co., Ltd, Wuhan 430040, China
This work was supported by grants from the Youth Talent Program of Beijing Life Science Academy (2024100CC0110), the Youth Talent Support Program of China National Tobacco Quality Supervision & Test Center (552024CR0010), the Basic Research Program of China National Tobacco Corporation (110202403001), the Science and Technology Project of China Tobacco Hubei Industrial Co., Ltd (2023JCXX3GC2A002), and Science and Technology Project of Hunan Tobacco Industrial Co., Ltd. (KY2026JC0023).
类器官作为干细胞衍生的体外三维自组织微型器官,已被证实能够重现体内器官的关键结构和功能特征。器官芯片是一种基于微流控技术的体外微生理系统,能够通过控制流体流动、物理生化因子梯度、细胞与细胞或细胞与细胞外基质间相互作用等更加精准地模拟器官微环境。类器官芯片融合了类器官的自组织能力与器官芯片的微环境精准调控优势,通过动态模拟生理微环境精准控制干细胞分化和组织形态发生,显著提升类器官结构及功能仿生性,并可对类器官的生长和行为进行多尺度动态监测。目前,已经发展出能够模拟机体多种靶器官的功能性类器官芯片,建立了串联多类器官芯片系统,实现了体外多器官相互作用和系统稳态的模拟。该技术为发育生物学、疾病建模、药物发现、精准医疗和毒理学研究提供了全新的平台。本文将系统探讨类器官芯片的发展历程、构建原理、技术方法及其在生物医学多领域的应用潜力,并就其当前面临的挑战与未来发展方向进行展望,旨在为类器官芯片的进一步发展和应用提供参考。
Organoid-on-a-chip technology represents a promising interdisciplinary advancement that merges two cutting-edge biomedical platforms: stem cell-derived organoids and microfluidics-based organ-on-a-chip systems. Organoids are self-organizing three-dimensional (3D) cell cultures that mimic the key structural and functional features of in vivo organs. However, traditional organoid culture systems are often static, lacking dynamic environmental cues and suffering from limitations such as batch-to-batch variability, low stability, and low throughput. Organ-on-a-chip platforms, by contrast, utilize microfluidic technologies to simulate the dynamic physiological microenvironment of human tissues and organs, enabling more controlled cell growth and differentiation. By integrating the advantages of organoids and organ-on-a-chip technologies, organoid-on-a-chip systems transcend the limitations of conventional 3D culture models, offering a more physiologically relevant and controllable in vitro platform. In organoid-on-a-chip systems, stem cells or pre-formed organoids are cultured in micro-engineered environments that mimic in vivo conditions, enabling precise control over fluid flow, mechanical forces, and biochemical cues. Specifically, these platforms employ advanced strategies including bio-inspired 3D scaffolds for structural support, precise spatial cell patterning via 3D bioprinting, and integrated biosensors for real-time monitoring of metabolic activities. These synergistic elements recreate complex extracellular matrix signals and ensure high structural fidelity. Based on structural complexity, organoid-on-a-chip systems are classified into single-organoid and multi-organoid types, forming a trajectory from unit biomimicry to systemic simulation. Single-organoid chips focus on highly biomimetic units by integrating vascular, immune, or neural functions. Multi-organoid chips simulate inter-organ crosstalk and systemic homeostasis, advancing complex disease modeling and PK/PD evaluation. This emerging technology has demonstrated broad application potential in multiple fields of biomedicine. Organoid-on-a-chip systems can recapitulate organ development in vitro, facilitating research in developmental biology. They mimic organ-specific physiological activities and mechanisms, showing promising applications in regenerative medicine for tissue repair or replacement. In disease modeling, they support the reconstruction of models for neurodegenerative, inflammatory, infectious, metabolic diseases, and cancers. These platforms also enable in vitro drug testing and pharmacokinetic studies (ADME). Patient-derived chips preserve genetic and pathological features, offering potential for precision medicine. Additionally, they reduce species differences in toxicology, providing human-relevant data for environmental, food, cosmetic, and drug safety assessments. Despite progress, organoid-on-a-chip systems face challenges in dynamic simulation, extracellular matrix (ECM) variability, and limited real-time 3D imaging, requiring improved materials and the integration of developmental signals. Current bottlenecks also include the high technical threshold for automation and the lack of standardized validation frameworks for regulatory adoption. Meanwhile, the concept of a “human-on-a-chip” has been proposed to mimic whole-body physiology by integrating multiple organoid modules. This approach enables systemic modeling of drug responses and toxicity, with the potential to reduce animal testing and revolutionize drug development. Future advancements in bio-responsive hydrogels and flexible biosensors will further empower these platforms to bridge the gap between bench-side research and personalized clinical interventions. In conclusion, organoid-on-a-chip technology offers a transformative in vitro model that closely recapitulates the complexity of human tissues and organ systems. It provides an unprecedented platform for advancing biomedical research, clinical translation, and pharmaceutical innovation. Continued development in biomaterials, microengineering, and analytical technologies will be essential to unlocking the full potential of this powerful tool.
刘瑞霞,张璟,李晓,柳毅,黄龙,侯宏卫.类器官芯片的构建及其在生物医学领域中的应用[J].生物化学与生物物理进展,2026,53(2):293-308
复制

扫码关注 生物化学与生物物理进展 ® 2026 网站版权 ICP:京ICP备05023138号-1 京公网安备 11010502031771号
